UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $385
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Dan Leonard has maintained a Buy rating on Bio-Rad Laboratories (NYSE:BIO) but has lowered the price target from $420 to $385.

May 08, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS maintains a Buy rating on Bio-Rad Laboratories but lowers the price target from $420 to $385.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals and potential for growth, the reduction in the price target could reflect adjustments in market conditions or expectations for the company's future performance. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100